Spots Global Cancer Trial Database for bispecific
Every month we try and update this database with for bispecific cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | NCT05498389 | Metastatic Lung... Advanced Lung N... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... EGFR Mutation-R... | EMB-01 Osimertinib | 18 Years - | Shanghai EpimAb Biotherapeutics Co., Ltd. | |
| A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma | NCT04728321 | Hepatocellular ... | AK104 lenvatini... AK104 | 18 Years - 75 Years | Akeso | |
| A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | NCT03922204 | Advanced Cancer Solid Tumor, Ad... B-cell Lymphoma... | MCLA-145 | 18 Years - | Merus N.V. | |
| A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma | NCT04444141 | Peripheral T-ce... | AK104 | 18 Years - 75 Years | Akeso | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL | NCT03751709 | B-Cell Acute Ly... ALL, Adult B-ALL | Blinatumomab Haplo-Mismatche... | 18 Years - | Cedars-Sinai Medical Center | |
| PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | NCT03650348 | HER2-positive B... HER2-positive G... HER2-positive B... HER2-positive S... | PRS-343 in Comb... | 18 Years - | Pieris Pharmaceuticals, Inc. | |
| MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb | NCT04649359 | Multiple Myelom... | Elranatamab (PF... | 18 Years - | Pfizer | |
| A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma | NCT05932290 | Multiple Myelom... | Elranatamab Standard of car... | 18 Years - | Pfizer | |
| A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | NCT03922204 | Advanced Cancer Solid Tumor, Ad... B-cell Lymphoma... | MCLA-145 | 18 Years - | Merus N.V. | |
| Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL | NCT03271515 | Leukemia Lymphoma | anti-CD19 anti-... | 18 Years - 70 Years | Beijing Doing Biomedical Co., Ltd. | |
| EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | NCT05498389 | Metastatic Lung... Advanced Lung N... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... EGFR Mutation-R... | EMB-01 Osimertinib | 18 Years - | Shanghai EpimAb Biotherapeutics Co., Ltd. | |
| A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | NCT04844073 | Squamous Cell C... Non-small Cell ... Colorectal Canc... | TAK-186 | 18 Years - | Takeda | |
| A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | NCT03922204 | Advanced Cancer Solid Tumor, Ad... B-cell Lymphoma... | MCLA-145 | 18 Years - | Merus N.V. | |
| A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma | NCT04444141 | Peripheral T-ce... | AK104 | 18 Years - 75 Years | Akeso | |
| Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | NCT05190445 | HER2-positive G... | Cinrebafusp alf... Cinrebafusp alf... | 18 Years - | Pieris Pharmaceuticals, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
